Pediatrix Medical Group, Inc. (NYSE:MD – Get Rating) CEO Mark S. Ordan sold 22,166 shares of the company’s stock in a transaction on Monday, November 21st. The stock was sold at an average price of $15.45, for a total transaction of $342,464.70. Following the sale, the chief executive officer now directly owns 346,645 shares in the company, valued at $5,355,665.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Pediatrix Medical Group Trading Up 1.5 %
MD stock opened at $15.81 on Friday. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.20 and a current ratio of 1.20. The company’s 50-day simple moving average is $17.00 and its 200 day simple moving average is $19.03. Pediatrix Medical Group, Inc. has a 52 week low of $14.48 and a 52 week high of $28.02. The company has a market capitalization of $1.31 billion, a PE ratio of 15.97, a price-to-earnings-growth ratio of 1.12 and a beta of 1.83.
Analysts Set New Price Targets
Several research firms have issued reports on MD. StockNews.com lowered shares of Pediatrix Medical Group from a “buy” rating to a “hold” rating in a research report on Thursday, October 20th. SVB Leerink dropped their price objective on shares of Pediatrix Medical Group from $20.00 to $16.00 and set a “market perform” rating on the stock in a research report on Friday, November 4th. William Blair reissued an “outperform” rating on shares of Pediatrix Medical Group in a research report on Thursday, November 3rd. Credit Suisse Group dropped their price objective on shares of Pediatrix Medical Group from $30.00 to $28.00 and set an “outperform” rating on the stock in a research report on Thursday, August 11th. Finally, BMO Capital Markets dropped their price objective on shares of Pediatrix Medical Group from $25.00 to $23.00 and set a “market perform” rating on the stock in a research report on Wednesday, August 10th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $20.00.
Hedge Funds Weigh In On Pediatrix Medical Group
About Pediatrix Medical Group
Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.
- Get a free copy of the StockNews.com research report on Pediatrix Medical Group (MD)
- Institutional Support for Analog Devices Remains High
- Is the 60/40 Portfolio Mix Still in Vogue?
- Three CBD Stocks to Dominate a Budding Industry
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Microsoft Shares: Is it Time to Back Up the Truck?
Receive News & Ratings for Pediatrix Medical Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pediatrix Medical Group and related companies with MarketBeat.com's FREE daily email newsletter.